エトレチナート
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/01/23 10:57:10」(JST)
[Wiki en表示]
|
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (July 2011) |
Etretinate
|
Systematic (IUPAC) name |
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate |
Clinical data |
AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
MedlinePlus |
a601010 |
Legal status |
? |
Routes |
Oral |
Pharmacokinetic data |
Half-life |
120 days |
Identifiers |
CAS number |
54350-48-0 N |
ATC code |
D05BB01 |
PubChem |
CID 5282375 |
DrugBank |
DB00926 |
ChemSpider |
4445538 Y |
UNII |
65M2UDR9AG Y |
KEGG |
D00316 Y |
ChEBI |
CHEBI:4913 Y |
ChEMBL |
CHEMBL464 Y |
Chemical data |
Formula |
C23H30O3 |
Mol. mass |
354.483 g/mol |
SMILES
- O=C(OCC)\C=C(\C=C\C=C(\C=C\c1c(cc(OC)c(c1C)C)C)C)C
|
InChI
-
InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+ Y
Key:HQMNCQVAMBCHCO-DJRRULDNSA-N Y
|
N (what is this?) (verify) |
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It was subsequently removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.
Contents
- 1 Properties
- 2 Precautions
- 3 Side effects
- 4 References
Properties[edit]
Etretinate has a low therapeutic index and a long elimination half-life (t1/2) of 120 days, which make dosing difficult.
Etretinate is an aromatic retinoid, and therefore highly lipophilic. It is stored and released from adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy.
Etretinate has been replaced by acitretin, a safer metabolite of etretinate.
Precautions[edit]
- Etretinate is a teratogen, and may cause birth defects long after use. Therefore, birth control is advised during therapy, and for at least three years after therapy has stopped.
- Etretinate should be avoided in children, as it may interfere with bone growth.
- If a patient has ever taken etretinate, he or she is not eligible to donate blood, due to the risk of birth defects.[1]
Side effects[edit]
- Hepatitis
- Pseudotumor cerebri
- Diffuse idiopathic skeletal Hyperostosis
References[edit]
- ^ UK Blood Transfusion and Tissue Transplantation Services[1]
Antipsoriatics (D05)
|
|
Topical |
Tars
|
|
|
Antracens
|
|
|
Psoralens
|
|
|
Other
|
- Fumaric acid
- vitamin D (Calcipotriol
- Calcipotriol/betamethasone
- Calcitriol
- Tacalcitol)
- Tazarotene
|
|
|
Systemic |
Psoralens
|
- Trioxysalen
- Methoxsalen
- Bergapten
|
|
Retinoids
|
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
|
noco (i/b/d/q/u/r/p/m/k/v/f)/cong/tumr (n/e/d), sysi/epon
|
proc, drug (D2/3/4/5/8/11)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients.
- Borges-Costa J, Silva R, Goncalves L, Filipe P, Soares de Almeida L, Marques Gomes M.SourceClinical University of Dermatology of Lisbon, Portugal. joaobc77@hotmail.com
- American journal of clinical dermatology.Am J Clin Dermatol.2011 Aug 1;12(4):271-6. doi: 10.2165/11586900-000000000-00000.
- BACKGROUND: Acute generalized pustular psoriasis (AGPP) is a rare variant of psoriasis that can be lethal without proper treatment. It can be caused by the withdrawal of corticosteroids and, among its extra-cutaneous manifestations, liver abnormalities are frequently under-reported or attributed to
- PMID 21495733
- Relative developmental toxicity potencies of retinoids in the embryonic stem cell test compared with their relative potencies in in vivo and two other in vitro assays for developmental toxicity.
- Louisse J, Gonen S, Rietjens IM, Verwei M.SourceDivision of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands. jochem.louisse@wur.nl
- Toxicology letters.Toxicol Lett.2011 May 30;203(1):1-8. Epub 2011 Feb 26.
- The present study determines the relative developmental toxicity potencies of retinoids in the embryonic stem (ES)-D3 cell differentiation assay of the embryonic stem cell test, and compares the outcomes with their relative potencies in in vivo and two other in vitro assays for developmental toxicit
- PMID 21362465
Japanese Journal
- エトレチナートが著効したグルカゴノーマを伴った壊死性遊走性紅斑の1例 (特集 紅斑症)
- 尋常性乾癬患者に生じた股関節症に対して人工股関節全置換術を施行した1例
- 峯岸 洋次郎,内山 勝文,福島 健介,高平 尚伸,南谷 淳,糸満 盛憲
- 関東整形災害外科学会雑誌 41(4), 171-176, 2010-08-01
- NAID 10026502345
Related Links
- Etretinate (trade name Tegison) is a medication developed by Hoffmann?La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It was subsequently removed from the United States market in 1998 and the Canadian market in ...
Related Pictures
★リンクテーブル★
[★]
- 英
- etretinate
- 商
- チガソン Tegison
[★]
- 英
- etretinate
- 関
- エトレチナート